Tumor-associated mRNA

Tumor-associated mRNA refers to a diverse group of messenger RNA molecules whose expression is altered, upregulated, or uniquely present in tumor cells compared to normal tissue. These mRNAs serve as templates for translating tumor-specific antigens and oncogenic proteins, underpinning many aspects of tumor growth, invasion, immune evasion, and metastasis. As such, they are exploited as targets for anti-cancer therapies, particularly mRNA vaccines engineered to introduce tumor antigens to the immune system, enabling T cell–mediated recognition and destruction of cancer cells. Moreover, tumor-associated mRNAs can function as tumor biomarkers for diagnostics and are transported in extracellular vesicles, contributing to cell–cell communication in the tumor microenvironment and potentially driving malignancy[2][3][4][7][8]. However, "tumor-associated mRNA" is not a single molecular entity but rather a category encompassing many different mRNAs corresponding to distinct tumors and patient contexts. The use of the term as a drug or antibody target is overly broad and lacks the specificity required for conventional molecular targeting; in drug discovery and structured databases, one would use the specific gene or protein name (e.g., "WT1 mRNA," "MAGE-A3 mRNA," etc.) in accordance with the antigen or oncogene in question.

Other names

Tumor antigen-encoding mRNACancer-associated mRNATumor-specific mRNAOncogenic mRNATumor mRNA (non-standard)

Vaccination: Delivery of tumor-associated mRNA into patient cells to express tumor antigens, stimulating an immune response (T cell activation/existing of memory cells). Gene silencing: Antisense or siRNA approaches inhibit translation of specific oncogenic mRNAs, reducing oncoprotein expression. Immunomodulation: mRNA-encoded cytokines (e.g., IL-12) or checkpoint blockade proteins enhance anti-tumor immunity.